🇺🇸 Apidra (insulin glulisine) in United States

27 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hyperkalaemia — 4 reports (14.81%)
  2. Nausea — 4 reports (14.81%)
  3. Nodal Arrhythmia — 3 reports (11.11%)
  4. Renal Failure — 3 reports (11.11%)
  5. Weight Decreased — 3 reports (11.11%)
  6. Abdominal Pain Upper — 2 reports (7.41%)
  7. Asthenia — 2 reports (7.41%)
  8. Atrial Septal Defect — 2 reports (7.41%)
  9. Bundle Branch Block Right — 2 reports (7.41%)
  10. Caesarean Section — 2 reports (7.41%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Apidra (insulin glulisine) approved in United States?

Apidra (insulin glulisine) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Apidra (insulin glulisine) in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.